image
Healthcare - Biotechnology - NASDAQ - US
$ 1.46
4.92 %
$ 87.3 M
Market Cap
-0.4
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one IGMS stock under the worst case scenario is HIDDEN Compared to the current market price of 1.46 USD, IGM Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one IGMS stock under the base case scenario is HIDDEN Compared to the current market price of 1.46 USD, IGM Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one IGMS stock under the best case scenario is HIDDEN Compared to the current market price of 1.46 USD, IGM Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IGMS

image
$18.0$18.0$16.0$16.0$14.0$14.0$12.0$12.0$10.0$10.0$8.0$8.0$6.0$6.0$4.0$4.0$2.0$2.0$0.0$0.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
2.68 M REVENUE
25.77%
-209 M OPERATING INCOME
20.83%
-196 M NET INCOME
20.54%
-153 M OPERATING CASH FLOW
20.41%
64.2 M INVESTING CASH FLOW
-6.14%
2.39 M FINANCING CASH FLOW
-97.92%
412 K REVENUE
-20.16%
-39 M OPERATING INCOME
39.46%
-36.6 M NET INCOME
40.34%
-34.8 M OPERATING CASH FLOW
9.29%
18 M INVESTING CASH FLOW
38.59%
420 K FINANCING CASH FLOW
-65.03%
Balance Sheet IGM Biosciences, Inc.
image
Current Assets 194 M
Cash & Short-Term Investments 184 M
Receivables 0
Other Current Assets 9.83 M
Non-Current Assets 72.1 M
Long-Term Investments 0
PP&E 71 M
Other Non-Current Assets 1.06 M
69.17 %3.70 %26.73 %Total Assets$265.7m
Current Liabilities 37.6 M
Accounts Payable 983 K
Short-Term Debt 7.12 M
Other Current Liabilities 29.5 M
Non-Current Liabilities 180 M
Long-Term Debt 38.1 M
Other Non-Current Liabilities 142 M
3.27 %13.58 %17.50 %65.20 %Total Liabilities$217.5m
EFFICIENCY
Earnings Waterfall IGM Biosciences, Inc.
image
Revenue 2.68 M
Cost Of Revenue 0
Gross Profit 2.68 M
Operating Expenses 211 M
Operating Income -209 M
Other Expenses -12.8 M
Net Income -196 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)3m03m(211m)(209m)13m(196m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-7785.74% OPERATING MARGIN
-7785.74%
-7308.51% NET MARGIN
-7308.51%
-406.45% ROE
-406.45%
-73.69% ROA
-73.69%
-88.68% ROIC
-88.68%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis IGM Biosciences, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -196 M
Depreciation & Amortization 9.11 M
Capital Expenditures -5.85 M
Stock-Based Compensation 38.3 M
Change in Working Capital -7.1 M
Others -4.27 M
Free Cash Flow -159 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets IGM Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for IGMS of $15.1 , with forecasts ranging from a low of $1.5 to a high of $25 .
IGMS Lowest Price Target Wall Street Target
1.5 USD 2.74%
IGMS Average Price Target Wall Street Target
15.1 USD 931.20%
IGMS Highest Price Target Wall Street Target
25 USD 1612.33%
Price
Max Price Target
Min Price Target
Average Price Target
25252020151510105500Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership IGM Biosciences, Inc.
image
Sold
0-3 MONTHS
25.7 K USD 4
3-6 MONTHS
39.4 K USD 4
6-9 MONTHS
130 K USD 7
9-12 MONTHS
299 K USD 8
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
Down -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a Turnaround IGM Biosciences (IGMS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. zacks.com - 2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ: IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 3 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 months ago
IGMS STOCK ALERT: Levi & Korsinsky Notifies IGM Biosciences, Inc. Investors of an Ongoing Investigation NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of IGM Biosciences, Inc. ("IGM Biosciences, Inc.") (NASDAQ:IGMS) concerning possible violations of federal securities laws. IGM issued a press release on January 9, 2025, "announc[ing] a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases. accessnewswire.com - 3 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS NEW YORK CITY, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 months ago
IGM Biosciences downgraded to Hold from Buy at Stifel Stifel downgraded IGM Biosciences to Hold from Buy with a price target of $2.50, down from $27. Th firm cites the company's "surprising decision" to discontinue all further development of its autoimmune and inflammatory disease applications for the downgrade. The strategic pivot will trigger the evaluation of both internal and external/ alternatives and an over 70% workforce reduction, the analyst tells investors in a research note. https://thefly.com - 3 months ago
IGM Biosciences downgraded to Underweight from Equal Weight at Morgan Stanley Morgan Stanley analyst Michael Ulz downgraded IGM Biosciences to Underweight from Equal Weight with a price target of $2, down from $12. The company announced discontinuation of its autoimmune programs, a 73% workforce reduction and plans to evaluate strategic alternatives, the analyst tells investors in a research note. The firm cites near-term uncertainty related to the future of IGM for the downgrade. https://thefly.com - 3 months ago
8. Profile Summary

IGM Biosciences, Inc. IGMS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 87.3 M
Dividend Yield 0.00%
Description IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Contact 325 East Middlefield Road, Mountain View, CA, 94043 https://igmbio.com
IPO Date Sept. 18, 2019
Employees 149
Officers Mr. Paul C. Graffagnino J.D. Senior Vice President of Legal Affairs Dr. Angus M. Sinclair Ph.D. Executive Vice President of Research Dr. Marvin S. Peterson Ph.D. Executive Vice President of Process Development & Manufacturing Ms. Elaine Sapinoso Senior Vice President of Quality Mr. Steven Weber Senior Vice President, Corporate Controller & Principal Accounting Officer Ms. Suzette Tauber Chief Human Resources Officer Dr. Lisa L. Decker Ph.D. Chief Business Officer Ms. Mary Beth Harler M.D. Chief Executive Officer & Director Mr. Misbah Tahir CPA Chief Financial Officer Mr. TS Harigopal Senior Vice President of Group Operations